Article

Pleiad chooses OmniComm and plans to use ophthalmology trial

As part of a partnership with OmniComm Systems Inc., Pleiad Devices will take advantage of the TrialMaster, an upcoming ophthalmology trial.

Fort Lauderdale, FL-Pleiad Devices has chosen OmniComm Systems Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials as its preferred vendor. Pleiad is an international Medical Device Contract Research Organization (CRO) with offices located in Europe and the United States and as a part of this partnership Pleiad will take advantage of the TrialMaster, an upcoming ophthalmology trial.

"Pleiad's clinical research team has years of experience in designing, organizing and managing clinical projects for medical device companies," said Stephen Brandao, vice president of business development for Pleiad Devices. "Over the years, our team has had experience with most of the EDC vendors in the marketplace. TrialMaster is one of the best EDC products that we have seen and we look forward to offering our medical device customers this premier service."

"Our CRO Preferred Program offers companies like Pleiad a true partner that will deliver the ancillary services that CROs need to be competitive in the evaluation process such as co-marketing and sales support for EDC. We offer the consummate partnership, both comprehensive company support and delivery of a first class EDC product," said Stephen Johnson, executive vice president of business development, services and client services and support. "At OmniComm, we are confident that our partnerships with CROs like Pleiad will ensure quality deliverables for the clinical research clients that we serve."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.